Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves CSL Behring’s Idelvion to treat hemophilia B
Idelvion is the albumin fusion protein that links recombinant coagulation factor IX with recombinant albumin to treat hemophilia B. CSL Behring claims that the drug is the first
Idelvion is the albumin fusion protein that links recombinant coagulation factor IX with recombinant albumin to treat hemophilia B. CSL Behring claims that the drug is the first
The rights were jointly owned by the university, researchers working at UCLA at the time of the discoveries and a research organization. The deal includes potential additional payments
The company earlier completed a phase 2 trial that successfully demonstrated the feasibility of administering Otiprio to pediatric patients with AOMT in an office setting. Under the second
The company will evaluate effectiveness in decreasing the number of acne-causing bacteria in patients at four weeks and assess the drug’s safety and tolerability. It is the first
It represents a compound annual growth rate (CAGR) of 8.4%. The report said that the UK’s life sciences sector features just under 5000 firms that develop, manufacture and
The JV, Avvinity Therapeutics, will be based in the UK. It has been launched to create a platform to discover and develop immuno-oncology therapeutics for solid tumours and
Rexall Health employs over 8,600 people in over 470 pharmacies throughout Canada. The company also operates Rexall Specialty Pharmacy, a division which offers clinical care and complex medication
Emtricitabine and tenofovir alafenamide are from Gilead Sciences, while rilpivirine is from Janssen Sciences Ireland UC. Odefsey is Gilead’s second TAF-based regimen to secure FDA approval and represents
The sBLA includes new data supporting the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor ALL. The filing was based on
ProStrakan agreed to pay AstraZeneca $70m upfront for the rights in the European Union as well as Iceland, Norway, Switzerland, and Liechtenstein. AstraZeneca will also receive future tiered